The FDA has announced the approval of a groundbreaking blood test designed to aid in the diagnosis of Alzheimer’s disease. This novel test offers a minimally invasive option for identifying biomarkers related to the disease, which may enhance early diagnosis and treatment strategies, paving the way for advancements in Alzheimer’s care.